TY  - JOUR
AU  - Colom-Fernández, Beatriz
AU  - Kreutzman, Anna
AU  - Marcos-Jiménez, Ana
AU  - García-Gutiérrez, Valentín
AU  - Cuesta-Mateos, Carlos
AU  - Portero-Sainz, Itxaso
AU  - Pérez-García, Yaiza
AU  - Casado, Luis Felipe
AU  - Sánchez-Guijo, Fermín
AU  - Martínez-López, Joaquín
AU  - Ayala, Rosa M
AU  - Boqué, Concha
AU  - Xicoy, Blanca
AU  - Montero, Isabel
AU  - Soto, César
AU  - Paz, Raquel
AU  - Silva, Gabriela
AU  - Vega-Piris, Lorena
AU  - Steegmann, Juan Luis
AU  - Muñoz-Calleja, Cecilia
PY  - 2019
DO  - 10.3389/fphar.2019.01340
SN  - 1663-9812
UR  - https://hdl.handle.net/10668/27195
T2  - Frontiers in pharmacology
AB  - Introduction: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In particular, dasatinib intake typically causes lymphocytosis, which has been...
LA  - en
KW  - CCR7
KW  - Dasatinib
KW  - chronic myeloid leukemia
KW  - lymphocytosis
KW  - migration
TI  - Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients.
TY  - research article
VL  - 10
ER  -